Welcome to the e-CCO Library!

search
Search by: 
Year: Category: Sub Type:
DOP064: ECCO expert consensus and topical review on treatment exit strategies in Inflammatory Bowel Disease
Year: 2018
Source: ECCO'18 Vienna
Authors: Doherty Glen
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP064: High rate of advanced neoplasia after detection of low-grade dysplasia in Inflammatory Bowel Disease patients with primary sclerosing cholangitis
Year: 2017
Source: ECCO'17 Barcelona
Authors: Ten Hove J.
Sclerosing Cholangitis, Colonoscopy, Dysplasia
Files: 1
DOP065: Less anti-infliximab antibody formation in paediatric Crohn's patients on concomitant immunomodulators
Year: 2016
Source: ECCO'16 DOP
Authors: Wolters V.
anti-TNF agents, therapeutic drug monitoring
Files: 1
DOP065: Long term cost effectiveness of tight control for Crohn’s Disease with adalimumab-based treatment: Economic evaluation beyond 48 weeks of CALM trial
Year: 2018
Source: ECCO'18 Vienna
Authors: Panaccione Remo
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP065: Use of chromoendoscopy versus white light endoscopy for colorectal cancer surveillance in Inflammatory Bowel Disease patients with primary sclerosing cholangitis; a six year experience
Year: 2017
Source: ECCO'17 Barcelona
Authors: Hartery K.
Chromoendoscopy, Colonoscopy, Dyplasia
Files: 1
DOP066: Developing a Core Outcome Set for Fistulising Perianal Crohn’s Disease
Year: 2018
Source: ECCO'18 Vienna
Authors: Sahnan Kapil
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP066: Disappearance of Anti-drug Antibodies to Infliximab and Adalimumab after Addition of an Immunomodulator in Patients with Inflammatory Bowel Disease
Year: 2016
Source: ECCO'16 DOP
Authors: Strik A.
anti-TNF agents, therapeutic drug monitoring
Files: 1
DOP066: Strict surveillance colonoscopy should be performed for the Ulcerative Colitis patients who underwent ileorectal anastomosis
Year: 2017
Source: ECCO'17 Barcelona
Authors: Anzai H.
Colonoscopy, Dysplasia, UC colorectal cancer surveillance
Files: 1
DOP067: Factors influencing infliximab and adalimumab antibody formation and 6 month retrospective follow-up in a Tertiary IBD Centre
Year: 2016
Source: ECCO'16 DOP
Authors: Digby-Bell J.
anti-TNF agents, therapeutic drug monitoring
Files: 1
DOP067: Risk of malignant and non-malignant complications of the rectal stump in patients with Inflammatory Bowel Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: Bogaerts J.
Post-operative IBD, Dysplasia, UC colorectal cancer surveillance
Files: 1
DOP067: Treatment discontinuation, flares and hospitalisations among biologic-naïve patients with IBD over the first year of treatment: A comparative effectiveness study of vedolizumab versus infliximab
Year: 2018
Source: ECCO'18 Vienna
Authors: Patel Haridarshan
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP068: Crohn’s Disease decision aid leads to more patients choosing combination therapy in a cluster randomised controlled trial
Year: 2018
Source: ECCO'18 Vienna
Authors: Siegel Corey A.
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP068: The virtual electronic chromoendoscopy (VEC) score in Ulcerative Colitis exhibits very good inter-rater agreement in scoring mucosal and vascular changes after computerised module training: A study across academic and community practice
Year: 2017
Source: ECCO'17 Barcelona
Authors: Trivedi P.
Chromoendoscopy, Colonoscopy, Narrow band imaging, UC Colorectal cancer surveillance
Files: 1
DOP069: Dose optimization using drug and antibody levels can benefit 50% patients prescribed anti TNF therapy compared to empiric dose adjustment
Year: 2016
Source: ECCO'16 DOP
Authors: Harrow P.
anti-TNF agents, therapeutic drug monitoring
Files: 1
DOP069: Improved quality of care quality of life for IBD patients using mobile based remote monitoring platform: A randomised control trial
Year: 2018
Source: ECCO'18 Vienna
Authors: Atreja Ashish
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP069: Natural history of dysplasia and colorectal cancer in IBD patients in Belgium tertiary care centers
Year: 2017
Source: ECCO'17 Barcelona
Authors: Cremer A.
Natural history, Dysplasia, UC colorectal cancer surveillance
Files: 1
DOP06: Non-invasive identification of adherent-invasive E. coli in patients with Crohn's Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Anthony Buisson
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP070: Development and pilot of an index to identify young people with Inflammatory Bowel Disease at risk of psychological morbidity
Year: 2018
Source: ECCO'18 Vienna
Authors: Lees Rupert T
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP070: Endoscopic response to induction therapy with TNF inhibitors is the best predictor of long term mucosal healing in Crohn’s Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: Alfaro I.
Crohn's disease, Disease activity indices, Adalimumab, Infliximab, Colonoscopy
Files: 1
DOP070: The relationship between vedolizumab drug concentrations at or before week 6 and remission at week 14 in ulcerative colitis patients from GEMINI 1
Year: 2016
Source: ECCO'16 DOP
Authors: Roblin X.
Ulcerative Colitis, therapeutic drug monitoring, vedolizumab
Files: 1